Literature DB >> 23076876

Corticotropin-releasing hormone (CRH) is expressed in the human cervical carcinoma cells (HeLa) and upregulates the expression of Fas ligand.

Eirini Taliouri1, Thomas Vrekoussis, Aikaterini Vergetaki, Theodore Agorastos, Antonis Makrigiannakis.   

Abstract

Corticotropin-releasing hormone acts as a stressor mediator in the human reproductive system. Corticotropin-releasing hormone (CRH) has been detected in several carcinomas of gynecological origin like breast, ovarian, and endometrial carcinomas. It was additionally shown that CRH could induce Fas ligand (FasL) expression in ovarian carcinoma cell lines. To determine whether CRH could also be expressed during cervical cancer development, we studied the expression of CRH using HeLa cells in an in vitro cervical cancer model. We further studied whether CRH could regulate FasL expression. In that context, HeLa cells were cultured in the presence or absence of 1 μM CRH. CRH and FasL expressions were assessed by indirect immunofluorescence, reverse transcription PCR, and Western blot. The current results indicated that in HeLa cells, CRH can significantly induce both FasL transcription and FasL translation. Taking into account previous studies already establishing a connection between FasL expression and tumor immunoescape in cervical cancer, it can be concluded that such immunoescape could be CRH dependent.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23076876     DOI: 10.1007/s13277-012-0519-8

Source DB:  PubMed          Journal:  Tumour Biol        ISSN: 1010-4283


  34 in total

1.  Thresholds of replication stress signaling in cancer development and treatment.

Authors:  Jiri Bartek; Martin Mistrik; Jirina Bartkova
Journal:  Nat Struct Mol Biol       Date:  2012-01-05       Impact factor: 15.369

2.  Prognostic significance of Fas and Fas ligand expressions in human esophageal cancer.

Authors:  M Shibakita; M Tachibana; D K Dhar; T Kotoh; S Kinugasa; H Kubota; R Masunaga; N Nagasue
Journal:  Clin Cancer Res       Date:  1999-09       Impact factor: 12.531

3.  The corticotropin releasing hormone gene is expressed in human placenta.

Authors:  M Grino; G P Chrousos; A N Margioris
Journal:  Biochem Biophys Res Commun       Date:  1987-11-13       Impact factor: 3.575

4.  Expression of FasL in squamous cell carcinomas of the cervix and cervical intraepithelial neoplasia and its role in tumor escape mechanism.

Authors:  Ramy Ibrahim; Helen Frederickson; Allyson Parr; Yvona Ward; Joel Moncur; Samir N Khleif
Journal:  Cancer       Date:  2006-03-01       Impact factor: 6.860

5.  Prognostic relevance of altered Fas (CD95)-system in human breast cancer.

Authors:  M Mottolese; S Buglioni; C Bracalenti; M A Cardarelli; L Ciabocco; D Giannarelli; C Botti; P G Natali; A Concetti; F M Venanzi
Journal:  Int J Cancer       Date:  2000-03-20       Impact factor: 7.396

Review 6.  Peripheral corticotropin-releasing hormone is produced in the immune and reproductive systems: actions, potential roles and clinical implications.

Authors:  Sophia Kalantaridou; Antonis Makrigiannakis; Emmanouil Zoumakis; George P Chrousos
Journal:  Front Biosci       Date:  2007-01-01

7.  Fas ligand expression by astrocytoma in vivo: maintaining immune privilege in the brain?

Authors:  P Saas; P R Walker; M Hahne; A L Quiquerez; V Schnuriger; G Perrin; L French; E G Van Meir; N de Tribolet; J Tschopp; P Y Dietrich
Journal:  J Clin Invest       Date:  1997-03-15       Impact factor: 14.808

Review 8.  The role of FasL and Fas in health and disease.

Authors:  Martin Ehrenschwender; Harald Wajant
Journal:  Adv Exp Med Biol       Date:  2009       Impact factor: 2.622

Review 9.  Stress and the female reproductive system.

Authors:  S N Kalantaridou; A Makrigiannakis; E Zoumakis; G P Chrousos
Journal:  J Reprod Immunol       Date:  2004-06       Impact factor: 4.054

10.  Corticotropin-releasing hormone, luteinizing hormone-releasing hormone, growth hormone-releasing hormone, and somatostatin-like immunoreactivities in biopsies from breast cancer patients.

Authors:  D R Ciocca; L A Puy; L C Fasoli; O Tello; J C Aznar; F E Gago; S I Papa; R Sonego
Journal:  Breast Cancer Res Treat       Date:  1990-05       Impact factor: 4.872

View more
  2 in total

1.  CRHR2/Ucn2 signaling is a novel regulator of miR-7/YY1/Fas circuitry contributing to reversal of colorectal cancer cell resistance to Fas-mediated apoptosis.

Authors:  Charalabos Pothoulakis; Monica Torre-Rojas; Marco A Duran-Padilla; Jonathan Gevorkian; Odysseas Zoras; Emmanuel Chrysos; George Chalkiadakis; Stavroula Baritaki
Journal:  Int J Cancer       Date:  2017-10-12       Impact factor: 7.316

2.  Tumor-Suppressor Gene NBPF1 Inhibits Invasion and PI3K/mTOR Signaling in Cervical Cancer Cells.

Authors:  Yun Qin; Xicai Tang; Mingxing Liu
Journal:  Oncol Res       Date:  2016-01-21       Impact factor: 5.574

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.